The US universe of chief medical information officers and hospital department heads is a few thousand people, concentrated in a few hundred health systems. That is a list, not an audience. Most launch plans treat it as an audience anyway, and the metrics they report are the proof.
When a brand with strong equity elsewhere in healthcare enters the US hospital and health system market, the first instinct is to commission a digital buy. Programmatic against a health IT audience segment, endemic trade placements, a paid social layer, and a reach-and-frequency plan that looks like every other healthcare launch.
That plan is solving a problem this buyer does not have. The clinical informatics leadership of US health systems is small enough to enumerate. Every person who will influence, evaluate, or sign the purchase can be named in advance. When the buyer can be named, reach is no longer the constraint, and a plan built to maximize it is optimizing the wrong variable.
Prescriber marketing works because the audience is large, distributed, and reachable in clinical context at scale. Hundreds of thousands of physicians, each making individual decisions many times a day. Reach and frequency are meaningful because the decision is individual and repeated.
An enterprise health IT purchase is the opposite on every axis. The decision is institutional, made once, by a committee, on a cycle measured in quarters. The CMIO is rarely the final signature. They are the internal champion who has to carry a business case through a chief financial officer, a chief information officer, a clinical governance body, and procurement. Media that reaches the CMIO ten times and gives them nothing to carry into that room has done very little.
The trade press for this audience is also unusually concentrated. A handful of publications carry most of the credibility, and the most influential of them are not conventional buys. Impressions purchased broadly against a "health IT" segment mostly land on people who are not on the list.
If the universe is a list, the plan should be measured against the list. Not impressions, not CPM, not click-through. Two numbers matter.
Penetration: of the named accounts that matter, how many have we reached at the level of the people who decide, and how many have engaged with something substantive rather than an ad unit.
Depth: within an account, how many of the roles on the buying committee have we reached, and how far has the champion progressed toward a business case they can defend internally.
Every channel decision that follows should be defensible in those terms. If a tactic cannot be tied to penetration or depth against named accounts, it is reach for its own sake, and reach is not scarce here.
Three shapes of plan hold up for a considered enterprise purchase. They are complementary, and the right mix depends on budget, sales readiness, and how much of the brand's existing equity transfers to this buyer.
CMIOs have to build an internal case to a finance leader. If the brand publishes the number that case cites, an annual index or a "state of" report built on real data from US health systems, the brand becomes infrastructure to the purchase rather than a vendor advertising at it. This is the highest-leverage idea on the list for a launch with a long buying cycle, because it is an asset that compounds rather than a campaign that ends.
This audience trusts its peers far more than it trusts vendors, and it gathers in a small number of professional homes. Closed-door roundtables, a standing advisory council that doubles as a content engine and a reference pipeline, and presence at the few moments a year when the whole universe is in one building. Almost none of this can be bought through a demand-side platform, which is exactly why it qualifies as something other than a typical digital buy.
Media that sells for the buyer rather than to them. A return-on-investment model they can adapt, peer benchmarks they can cite, board-ready material they can present, and procurement-ready documentation that removes friction from the last mile. Most launches ignore the committee entirely and are surprised when a well-engaged CMIO cannot get a deal through.
Underneath these, a supporting layer still earns its place: a tight presence in the concentrated trade press this audience actually reads, and a paid social layer targeted against the named-account list rather than a broad segment. Supporting, not leading.
Whether the launch leads with the parent brand or builds separation for a new buyer. Whether a US sales motion exists to receive what the plan generates, because media into an empty pipeline is wasted. What "success" will be measured as ninety days after launch, since awareness, pipeline, and category creation are three different plans. And what the remit actually is, strategy through execution or strategy alone.
Those answers determine the plan. Answering them before a single placement is bought is the difference between a launch that reaches a list and one that moves it.
Start with the named-account question. Cadence helps brands entering the US hospital market define the list, the committee, and the metric before the media is bought.